# Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

> **NCT04745130** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Sintilimab, Cetuximab, Regorafenib,Combine,mCRC

## Interventions

- **DRUG:** Sintilimab，regofinib，cetuximab
- **DRUG:** KRAS BRAF mutant Sintilimab + regafinil

## Key facts

- **NCT ID:** NCT04745130
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-02
- **Final completion:** 2024-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745130, "Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04745130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*